Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Evaluations for the gliptins

The Regional Drug and Therapeutics Centre has produced New Drug Evaluations for sitagliptin (Januvia®) and vildagliptin (Galvus®).

The evaluation of sitagliptin recommends that this drug "may be considered as an option for patients who fail to achieve glycaemic control despite an adequate trial of established first and second-line regimens". It also notes that long term safety and efficacy data are lacking.

The evaluation for vildagliptin makes the same recommendations and qualifies that an "appropriate place in treatment protocols is presently undetermined".

The gliptins are a new drug class with data to support statistically significant improvements in HbA1c. However, long term efficacy and safety are unknown and there are no data to demonstrate improvements in morbidity and mortality.

Action: The limitations above currently place these drugs as a last line option before moving to insulin in patients who have poor glycaemic control on established treatments or who are intolerant to established agents.

Share 'Drug Evaluations for the gliptins' on Email Share 'Drug Evaluations for the gliptins' on Delicious Share 'Drug Evaluations for the gliptins' on Digg Share 'Drug Evaluations for the gliptins' on Facebook Share 'Drug Evaluations for the gliptins' on Google+ Share 'Drug Evaluations for the gliptins' on reddit Share 'Drug Evaluations for the gliptins' on StumbleUpon Share 'Drug Evaluations for the gliptins' on Twitter

atomic-wealth

One Comments to “Drug Evaluations for the gliptins”

  1. Gliptins lack data...

    The UK's Regional Drug and Therapeutics Centre has produced New Drug Evaluations for sitagliptin (Januvia®) and vildagliptin (Galvus®)....

    Trackback by Trusted.MD Network — April 25, 2008 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,668 spam comments.

atomic-wealth
fond-illness
summer